SRR1378841
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.420
- PANCREAS_BETA_CELLS+0.412
- KRAS_SIGNALING_DN+0.380
- APICAL_SURFACE+0.367
- COAGULATION+0.346
- IL6_JAK_STAT3_SIGNALING+0.332
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.330
- MYOGENESIS+0.324
- TNFA_SIGNALING_VIA_NFKB+0.312
- ALLOGRAFT_REJECTION+0.309
Top 10 suppressed
- PROTEIN_SECRETION-0.537
- OXIDATIVE_PHOSPHORYLATION-0.526
- DNA_REPAIR-0.496
- MYC_TARGETS_V2-0.488
- MYC_TARGETS_V1-0.473
- MITOTIC_SPINDLE-0.369
- E2F_TARGETS-0.349
- PEROXISOME-0.329
- ADIPOGENESIS-0.299
- ANDROGEN_RESPONSE-0.296
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1477615 | GTEX | — | 0.982 |
| 2 | SRR602271 | GTEX | — | 0.966 |
| 3 | SRR1336548 | GTEX | — | 0.962 |
| 4 | SRR1414424 | GTEX | — | 0.943 |
| 5 | SRR1429162 | GTEX | — | 0.935 |
| 6 | SRR1383612 | GTEX | — | 0.933 |
| 7 | MNG1146 | — | — | 0.929 |
| 8 | SRR601787 | GTEX | — | 0.923 |
| 9 | BS_YG0A13JH | pilocytic astrocytoma | — | 0.921 |
| 10 | SRR1354577 | GTEX | — | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.412 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.380 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.367 | Temsirolimus | — uncovered |
| COAGULATION | 0.346 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.332 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| MYOGENESIS | 0.324 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.312 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.309 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.282 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.267 | Inavolisib | — uncovered |
| COMPLEMENT | 0.249 | Inavolisib | — uncovered |
| HYPOXIA | 0.228 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.226 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.186 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.156 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.099 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.090 | Inavolisib | — uncovered |